Acadia CEO Uli Hacksell said that the molecule has demonstrated an attractive profile and has distinctly different properties from other glaucoma compounds advanced under the collaboration.
Both the companies had entered into partnership agreement to leverage Acadia’s R&D platform to discover and develop new therapeutics for glaucoma and other ophthalmic conditions.
As part of the glaucoma collaboration agreement, Allergan will focus on development and commercialization of products, whereas Acadia will receive payments on achieving clinical and regulatory milestones as well as royalties on future product sales across the globe.
"This program benefits greatly from Allergan’s expertise and leadership in the eye care field and further illustrates the combined strength of our joint discovery capabilities," Hacksell said.